Related Experiment Videos
Pharmacogenomics of statin response
Lara M Mangravite1, Russell A Wilke, Jiong Zhang
1Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA.
Current Opinion in Molecular Therapeutics
|December 4, 2008
Summary
Genetic variations influence how well statins work and their side effects. While individual gene effects are small, combined genetic factors may significantly impact statin response and cardiovascular disease risk.
Area of Science:
- Pharmacogenomics
- Cardiovascular Disease Research
- Lipid Metabolism
Background:
- Statins are primary treatments for lowering LDL-cholesterol and reducing cardiovascular disease (CVD) risk.
- Patient response to statin therapy exhibits significant variability.
- Genetic factors are hypothesized to influence both the efficacy and adverse effects of statins.
Purpose of the Study:
- To investigate the role of genetic variations in modifying statin efficacy.
- To identify genetic polymorphisms associated with statin-induced adverse drug reactions.
- To explore the impact of pharmacogenomics on statin-mediated LDL-cholesterol reduction and CVD risk.
Main Methods:
- Candidate-gene association studies.
- Genome-wide association studies (GWAS) for statin response.
- Analysis of pharmacogenomic data from clinical trials.
Main Results:
- Identification of genetic polymorphisms linked to statin response.
- Evidence suggests that individual genetic determinants have a minor effect on overall response.
- The cumulative impact of multiple genetic variations may substantially influence treatment outcomes.
Conclusions:
- Pharmacogenomic approaches are uncovering genetic factors influencing statin therapy.
- Combined genetic effects, rather than single polymorphisms, may be key to understanding response variability.
- Further replication in diverse populations and clinical trials is necessary to establish clinical utility.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...